




IL6/STAT3 signaling hijacks ER enhancers to drive breast cancer metastasis 1 
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The cytokine interleukin 6 (IL6) and its downstream effector STAT3 constitute a key oncogenic 2 
pathway, which has been thought to be functionally connected to estrogen receptor α (ER) in breast 3 
cancer. We demonstrate that IL6/STAT3 signaling drives metastasis in ER+ breast cancer 4 
independent of ER. STAT3 hijacks a subset of ER enhancers to drive a distinct transcriptional 5 
program. Although these enhancers are shared by both STAT3 and ER, IL6/STAT3 activity is 6 
refractory to standard ER targeted therapies. Instead, inhibition of STAT3 activity using JAK 7 
inhibitor ruxolitinib decreases breast cancer invasion in vivo. Therefore, IL6/STAT3 and ER 8 
oncogenic pathways are functionally decoupled highlighting the potential of IL6/STAT3-targeted 9 
therapies in ER+ breast cancer. 10 
 11 
Significance 12 
The ubiquitous oncogenic IL6/STAT3 pathway has been linked to cancer progression in many 13 
solid tumors, and it is therefore a prime candidate for the development of anti-cancer therapies. In 14 
breast cancer, IL6/STAT3 signaling has previously been linked ER function. Here, we demonstrate 15 
that IL6/STAT3 signaling induces a more invasive and metastatic phenotype in breast cancer 16 
independent of ER and its pioneer factor FOXA1 by hijacking shared ER-FOXA1-STAT3 17 
enhancers. This effectively decouples these two oncogenic pathways and highlights the potential 18 
for targeting the IL6/STAT3 pathway in ER+/IL6+/pSTAT3+ breast cancer to inhibit this 19 







Interleukin-6 (IL6) is a pleiotropic cytokine that plays a central role in both normal human 1 
physiology and disease (Hunter and Jones, 2015; Mauer et al., 2015). IL6 binding to its receptor 2 
complex IL6R/gp130, activates downstream Janus kinases (JAKs), which subsequently activate 3 
Signal transducer and activator of transcription 3 (STAT3) through phosphorylation of Tyrosine 4 
705 (Mauer et al., 2015). IL6/STAT3 signaling has been shown to play an important role in tumor 5 
progression in many solid tumor types (e.g. breast cancer and lung cancer) by inducing epithelial-6 
to-mesenchymal transition (EMT) and angiogenesis (Johnson et al., 2018). Thus, the IL6/STAT3 7 
pathway is an attractive pharmacological target in oncology, and multiple different approaches to 8 
target this pathway are being pursued pre-clinically as well as clinically including targeting of 9 
upstream JAKs (e.g. ruxolitinib), direct targeting of STAT3 phosphorylation and activation (e.g. 10 
OPB compounds) and downregulating STAT3 expression (e.g. AZD9150) (Huynh et al., 2018; 11 
Wong et al., 2017).  12 
The estrogen receptor  (ER) is a key driver of tumor growth and metastasis in ER+ breast cancer, 13 
and anti-estrogen treatments (e.g. aromatase inhibitors, tamoxifen and fulvestrant) are the standard 14 
of care for patients with this disease (Matutino et al., 2018). ER cooperates with several other 15 
transcription factors to control gene expression and ultimately tumor growth (Siersbaek et al., 16 
2018), most notably the forkhead transcription factor FOXA1, which is a pioneer factor important 17 
for facilitating ER-chromatin association (Hurtado et al., 2011). IL6 has been implicated as a driver 18 
in pre-clinical models of ER+ breast cancer (Casneuf et al., 2016; De Luca et al., 2012; Ibrahim et 19 
al., 2016), and high IL6 serum and tumor levels have been associated with aggressiveness and poor 20 
outcome in patients (Bachelot et al., 2003; Jiang et al., 2017; Salgado et al., 2003). It has been 21 
reported that ER and IL6/STAT3 can modulate the transcriptional activity of each other in 22 





complex (Binai et al., 2010; Yamamoto et al., 2000). IL6/STAT3 signaling and ER function are 1 
therefore thought to be functionally connected. Here, we investigate the transcriptional 2 
mechanisms through which IL6/STAT3 signaling controls breast cancer metastasis and its 3 
functional connection to ER and FOXA1. 4 
 5 
Results 6 
IL6/STAT3 signaling drives tumor growth and metastasis in an intraductal breast cancer xenograft 7 
model 8 
To first establish the functional importance of IL6 signaling for tumor progression in ER+ breast 9 
cancer, we took advantage of a recently developed mouse xenograft model using intraductal 10 
injection of human cancer cells into the mammary ducts (Fiche et al., 2019; Sflomos et al., 2016). 11 
This mouse intraductal (MIND) model recapitulates the different stages of breast cancer 12 
development seen in the clinic, including metastasis to clinically relevant distant organs such as 13 
liver, lung, bone and brain. Since mouse IL6 does not bind to the human receptor (Hammacher et 14 
al., 1994), we generated luciferase-expressing T47D cells that also express human IL6 (Figure 15 
S1A), which induces constitutive phosphorylation and activation of STAT3 (Figure S1B), and 16 
injected these cells intraductally into the mouse mammary glands of NSG females. IL6 increased 17 
phosphorylation of STAT3 in the primary tumors as expected (Figure 1A and Figure S1C) to a 18 
level comparable to that seen in ER+/pSTAT3+ patients (Figure S1D). Interestingly, IL6 expression 19 
significantly increased the growth rate of the primary tumor, relative to non-IL6 expressing control 20 
MIND tumors (Figure 1B and S1E). Importantly, activation of the IL6/STAT3 pathway 21 
significantly increased metastasis to the lungs by ~5-fold, and produced a trend towards increased 22 





relevant xenograft model, activation of the IL6/STAT3 pathway in ER+ tumors promotes 1 
metastatic spread. Consistently, activation of the IL6-STAT3 pathway, as indicated by positivity 2 
for IL6 and pSTAT3Y705 by immunohistochemistry (IHC) (Ahmad et al., 2018; Aleskandarany et 3 
al., 2016), is associated with lower breast cancer-specific survival (BCSS, 54.2 (IL6+/pSTAT3+) 4 
versus 85.3 (all other cases) months; Log-rank p = 0.022) and overall survival (OS, 47.2 5 
(IL6+/pSTAT3+) versus 73.6 (all other cases) months; Log-rank p = 0.003) in patients (All patients: 6 
Figure 1E,F; ER+ patients: Figure S1G,H).  7 
 8 
Activated STAT3 associates with the ER/FOXA1 complex on chromatin 9 
To understand the mechanisms underlying IL6-induced activation of tumor progression, we 10 
performed quantitative multiplexed rapid immunoprecipitation mass spectrometry of endogenous 11 
proteins (qPLEX-RIME), an unbiased protein interactome method we recently developed 12 
(Papachristou et al., 2018). Strikingly, ER qPLEX-RIME under full estrogenic conditions 13 
demonstrated that increased association between ER and STAT3 was the only significant change 14 
in the ER complex following IL6-induced phosphorylation of STAT3 (Figure 2A and Figure 15 
S2A,B). In contrast to ovarian cancer (Wang et al., 2015), Ser167 phosphorylation of ER was not 16 
induced by IL6 (Figure S2C). qPLEX-RIME of STAT3 showed that IL6 also increased the 17 
association between STAT3 and several well-known ER-associated factors such as FOXA1 and 18 
nuclear receptor coactivator 3 (NCOA3) (Figure 2A and Figure S2B). We could validate an 19 
increased association between ER and (p)STAT3 in response to IL6 using proximity ligation assay 20 
(PLA) (Figure S2D). Importantly, ER qPLEX-RIME in nine patient tumor samples (five primary 21 
ER+ tumors and four ER+ pleural effusions – see Table S1) demonstrated that STAT3 was a robust 22 





was no difference in this association between primary solid tumors and pleural effusions (Figure 1 
S2E), indicating that ER and STAT3 associate both in primary and metastatic cancer cells. 2 
To understand the association between ER/FOXA1 and STAT3 at the genomic level, we 3 
performed chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) of ER, 4 
pSTAT3, total STAT3 and FOXA1 in response to short-term IL6 stimulation under full estrogenic 5 
conditions in T47D cells (Figure 3A and Figure S3A). IL6 induced extensive binding of pSTAT3 6 
and total STAT3 to chromatin, whereas there was very little binding in the absence of IL6, 7 
demonstrating the necessity for exogenous IL6 for recruitment of STAT3 to chromatin (Figure 3A 8 
and Figure S3B). Consistent with the qPLEX-RIME data, pSTAT3 and total STAT3 chromatin 9 
binding in response to IL6 overlapped extensively with both ER and FOXA1 binding (Figure 3A 10 
and Figure S3C). Interestingly, binding of ER and FOXA1 was induced at a subset of sites shared 11 
between pSTAT3 and ER in response to IL6 (Figure 3B). These putative cis-regulatory elements 12 
were enriched for the STAT3 motif (Figure S3D), indicating that STAT3 likely mediates 13 
recruitment of ER/FOXA1 to these sites. Importantly, the extensive overlap in genomic binding 14 
of STAT3, ER and FOXA1 was validated in MCF7 cells (Figure S4A and S4B) and two 15 
ER+/pSTAT3+ primary breast tumors (Figure 3C). 16 
 17 
IL6/STAT3 signaling controls a distinct gene program through shared STAT3-ER-FOXA1 binding 18 
sites  19 
To link these binding events to transcriptional regulation, we profiled differential gene expression 20 
events in response to IL6 under full estrogenic conditions using RNA-seq in both T47D and MCF7 21 
cells (Figure 4A and Figure S5A). Most of the genes in both cell lines changing significantly in 22 





Figure 4A and Figure S5A), consistent with the global recruitment of the transcriptional activator 1 
STAT3 to chromatin in response to IL6 (Figure 3A and S3B). Gene Set Enrichment Analysis 2 
(GSEA) showed that although some of the induced genes are known estrogen responsive genes, 3 
including MYC and X-box binding protein 1 (XBP1), most of the IL6 induced genes belong to 4 
different gene pathways (Figure 4A, right). This includes genes linked to an aggressive and more 5 
metastatic breast cancer phenotype, including B-cell lymphoma 3-encoded protein (BCL3) 6 
(Wakefield et al., 2013), intracellular adhesion molecule 1 (ICAM1) (Di et al., 2016) and vascular 7 
endothelial growth factor A (VEGFA) (Kim et al., 2017). Importantly, binding sites shared between 8 
pSTAT3, ER and FOXA1 were the most enriched sites adjacent to the IL6 target genes (Figure 4B 9 
and Figure S5B), suggesting that cis-regulatory elements near IL6 target genes are more likely to 10 
be co-bound by all three transcription factors. 11 
Correlation of RNA-seq and Assay for Transposase-Accessible Chromatin sequencing (ATAC-12 
seq) signal within 500 kb across multiple TCGA patient tumors has recently allowed Corces et al. 13 
to infer direct target genes controlled by regulatory regions in patients without relying solely on 14 
gene proximity (Corces et al., 2018). We took advantage of these established promoter-enhancer 15 
connections to infer direct target genes controlled by pSTAT3-ER binding sites. Importantly, 16 
ATAC-seq peaks in patient breast tumors that are occupied by both pSTAT3 and ER in T47D cells 17 
or patients are functionally connected to the control of IL6 target gene expression through 18 
promoter-enhancer connections more than expected by chance (Figure 4C,D and Figure S5C, 19 
approximate random permutation p value <0.0001). In contrast, sites only bound by pSTAT3 do 20 
not show this enrichment (Figure 4C). Furthermore, shared pSTAT3-ER sites are more highly 21 
connected to regulation of IL6 target genes through expression quantitative trait loci (eQTL) than 22 





signals through shared pSTAT3-ER sites to activate its target gene program, which is distinct from 1 
the classical estrogen responsive gene program.  2 
 3 
IL6/STAT3 signaling induces the establishment of shared ER-FOXA1-STAT3 enhancers 4 
The key role of shared ER-pSTAT3 binding sites in driving the IL6 gene program led us to 5 
investigate the role of IL6/STAT3 signaling in establishing active regulatory regions at these 6 
shared sites. First, we assessed changes in chromatin accessibility in response to IL6 using ATAC-7 
seq and compared this to the effect of depleting FOXA1, which is known to be involved in 8 
chromatin remodeling at ER binding sites (Hurtado et al., 2011). In response to short-term IL6 9 
treatment, we identify a remarkable dynamic response with 8,723 and 3,159 sites showing 10 
increased and decreased accessibility, respectively (Figure S6A,B). This is comparable to the 11 
extent of chromatin remodeling observed in response to two days of FOXA1 knock down (7,718 12 
and 8,529 sites with increased and decreased accessibility, respectively, in the IL6 condition 13 
(Figure S6A,C)). Interestingly, IL6-induced chromatin accessibility is associated with increased 14 
binding of ER and FOXA1 in addition to pSTAT3 at shared sites, but chromatin remodeling is 15 
largely independent on the presence of FOXA1 (Figure 5A,B and S6D). Strikingly, ER binding to 16 
these IL6-dependent sites is also not dependent on FOXA1 (Figure 5B, top), which has previously 17 
been shown to be important for most classical estrogen-dependent ER binding events (Hurtado et 18 
al., 2011) (Figure 5B, bottom). This demonstrates that IL6/STAT3 signaling induces ER and 19 
FOXA1 binding at a subset of binding sites, where FOXA1 is not a pioneer factor. In contrast, 20 
chromatin accessibility and binding of ER and pSTAT3 at a distinct subset of shared sites is highly 21 
dependent on FOXA1, but shows limited response to IL6 treatment, despite robust IL6-induced 22 





binding sites are highly enriched for the STAT3 and FOXA1 motifs, respectively (Figure S6E), 1 
indicating that the selective initiating function of these factors is at least partly dictated by the 2 
DNA sequence. Importantly, profiling of the well-established active chromatin mark H3K27ac 3 
(Creyghton et al., 2010) together with the mostly distal location of the shared binding sites (Figure 4 
S6F) shows that IL6-induced chromatin remodeling is associated with robust enhancer activation 5 
independent of FOXA1 (Figure 5B, top). Similarly, IL6 has no effect on H3K27ac at sites 6 
dependent on the pioneering function of FOXA1 (Figure 5B, bottom). This further demonstrates 7 
that distinct initiating functions of IL6/STAT3 and FOXA1 induce activation of distinct enhancers.  8 
  9 
IL6/STAT3 hijacks shared ER-FOXA1-pSTAT3 enhancers to drive target genes independent of 10 
ER/FOXA1 function 11 
The IL6-dependent shared ER-FOXA1-pSTAT3 binding sites defined above are more highly 12 
enriched near IL6-activated genes than FOXA1-dependent sites (Figure 5C), indicating that they 13 
directly control the IL6 target gene program. To determine the functional roles of STAT3, ER and 14 
FOXA1 for the transcriptional response to IL6, we therefore performed RNA-seq in response to 15 
IL6 stimulation following siRNA-mediated depletion of these factors in T47D cells (Figure S6A). 16 
As expected, STAT3 is critical for IL6-induced transcriptional activation (Figure 5D and S6G). 17 
This could be validated by RNA-seq in two STAT3-/- MCF7 clones generated using a 18 
CRISPR/Cas9 deletion approach (Figure 5E and S6H). FOXA1-dependent genes are largely 19 
distinct from IL6-dependent genes indicating that these factors drive different gene programs 20 
(Figure S6I). Consistently, FOXA1 is not required for the transcriptional response to IL6 (Figure 21 
5D and S6G), which is consistent with the finding that FOXA1 is not required for activation of 22 





binding sites (Figure 5B), we hypothesized that ER rather than FOXA1 binding in response to 1 
IL6/STAT3-induced chromatin remodeling was important for transcriptional activation. 2 
Surprisingly however, ER is not required for the transcriptional activation of genes near IL6-3 
dependent enhancers (Figure 5D) or the IL6 gene program as a whole (Figure S6G). To validate 4 
this, we used the potent and rapid ER-degrader fulvestrant in MCF7 cells. Consistent with our 5 
findings using siRNA-mediated knock down of ER in T47D cells, four-hour treatment with 6 
fulvestrant under full estrogenic conditions (Figure S6H) did not affect transcriptional activation 7 
of the IL6-induced genes (Figure 5E), although it robustly decreased the classical ER target gene 8 
program (Figure S6J). Thus, FOXA1 and ER are not required for the transcriptional response to 9 
IL6/STAT3 signaling. Similarly, FOXA1-induced genes near FOXA1-dependent shared binding 10 
sites do not respond to IL6, but depend on FOXA1 and ER (Figure 5F). Taken together, these 11 
results demonstrate that IL6/STAT3 and ER/FOXA1 drive distinct and functionally independent 12 
gene programs from shared regulatory regions.   13 
 14 
Ruxolitinib inhibits the IL6/STAT3 target gene program and invasion in patient-derived tumors 15 
Consistent with the functionally independent roles of ER and STAT3 at shared regulatory regions 16 
described above, pSTAT3 and ER are independent prognostic factors for BCSS and OS in IL6+ 17 
patients as determined by multivariate analyses (Figure S7A,B). To investigate whether the 18 
IL6/STAT3 target gene program is also refractory to ER-targeted therapies in patients, we took 19 
advantage of matched pre- and post-treatment gene expression data from ER+ breast cancer 20 
patients treated with the aromatase inhibitors anastrozole (Dunbier et al., 2013) and letrozole (Selli 21 
et al., 2019) in the neoadjuvant setting. Importantly, while around one third of Hallmark (Liberzon 22 





acid receptor alpha (RARA), TFF1, growth regulation by estrogen in breast cancer 1 (GREB1), 1 
cyclin D1 (CCND1)) were repressed by aromatase inhibitor treatment in both data sets, IL6 target 2 
genes were largely unaltered (Figure 6A and S7C). To investigate whether pharmacological 3 
targeting of IL6/STAT3 signaling instead could inhibit this pathway to potentially benefit patients, 4 
we took advantage of a recently developed ex vivo explant system (Figure S7D) (Centenera et al., 5 
2018) to investigate the response of ER+/PR- PDX tumors to the JAK inhibitor ruxolitinib. 6 
Ruxolitinib inhibited both basal and IL6-induced STAT3 phosphorylation in these explant models 7 
(Figure 6B,C and S7E,F). Importantly, ruxolitinib treatment also decreased expression of the 8 
proliferation maker Ki67 (Figure 6B,C) and expression of the IL6 target genes MYC, ETS-related 9 
transcription factor Elf3 (ELF3) and BCL3 (Figure 6D).  10 
To investigate how inhibition of IL6/STAT3 affects tumor progression in a clinically relevant 11 
setting of endocrine resistance in vivo, we took advantage of a highly resistant ER+/PR+ PDX, 12 
where the patient progressed in chemotherapy, aromatase inhibitors, fulvestrant and palbociclib 13 
(CDK4/6 inhibitor). Ruxolitinib treatment in this MIND PDX model significantly, but very 14 
modestly, decreases primary tumor growth (~20%, Figure 6E), despite very efficient on-target 15 
efficacy as shown by the absence of pSTAT3 upon ruxolitinib treatment (Figure 6F,G). This is 16 
similar to the modest response to fulvestrant (which the patient progressed on) or the combination 17 
treatment (~30% reduction in tumor growth), which are also associated with decreased Ki67 levels 18 
(Figure 6E-H). Interestingly however, ruxolitinib or the combination treatment dramatically 19 
decreased the ability of the tumor cells to invade through the myoepithelial layer and into the 20 
surrounding tissue (Figure 6I). This was not observed in mice treated with only fulvestrant despite 21 
efficient inhibition of ER function as indicated by reduced expression of the classical ER target 22 





efficiently inhibit progression of a highly endocrine-resistant tumor, particularly by specifically 1 
inhibiting the invasive potential of the cancer cells. 2 
 3 
Discussion 4 
We demonstrate that IL6/STAT3 signaling drives metastasis in MIND xenograft models of ER+ 5 
breast cancer. Previous reports have shown that pSTAT3 is associated with good outcome in breast 6 
cancer (Aleskandarany et al., 2016; Sonnenblick et al., 2018), but here we show in the Nottingham 7 
cohort (Ahmad et al., 2018; Aleskandarany et al., 2016) that pSTAT3 is associated with poor 8 
outcome, when specifically focusing on patients with an IL6+ tumor. This is consistent with our in 9 
vivo data and highlights the clinical importance of the IL6/STAT3 pathway.  10 
Interestingly, IL6/STAT3 induces chromatin remodeling to establish shared ER-FOXA1-pSTAT3 11 
enhancers independent of the pioneering activity of FOXA1. This demonstrates that pioneering 12 
activity is context-dependent and different factors can have pioneering or initiating function at 13 
different sites consistent with previous findings for steroid receptors (Paakinaho et al., 2019). 14 
Surprisingly, in contrast to previous reports suggesting functional crosstalk between IL6/STAT3 15 
and ER (Speirs et al., 2000; Yamamoto et al., 2000), IL6/STAT3 drives a distinct oncogenic gene 16 
program independent of ER/FOXA1 function by hijacking these shared ER-FOXA1-pSTAT3 17 
enhancers. Thus, ER and FOXA1 have limited functional importance and are largely silent 18 
passengers at these IL6/STAT3-driven enhancers. Consistent with independent roles of 19 
ER/FOXA1 and IL6/STAT3, we show that pSTAT3 and ER are independent prognostic factors in 20 
breast cancer. Importantly, IL6/STAT3 is therefore also resistant to endocrine therapy, yet 21 
responsive to IL6/STAT3-targeted therapy like ruxolitinib. This decouples these pathways and 22 





functionally independent oncogenic pathways (Figure 7). We therefore propose that treatment with 1 
IL6/STAT3-targeting agents will benefit ER+/IL6+/pSTAT3+ breast cancer patients in the adjuvant 2 
or metastatic setting by inhibiting a tumor microenvironment-driven metastatic pathway that is not 3 
targeted by current endocrine therapies. In this regard, it is interesting to note the recent structure-4 
based design of SD36 as a small molecule that specifically and efficiently induces proteosomal 5 
degradation of STAT3 protein to inhibit growth of lymphoma and leukemia xenografts (Bai et al., 6 
2019). Furthermore, a STAT3 inhibitor, TTI-101, is being investigated in a recently established 7 
phase I clinical trial for safety and efficacy in multiple cancers including breast cancer 8 
(NCT03195699). While many of the IL6/STAT3 target genes described here have previously been 9 
linked to a more aggressive and metastatic phenotype (e.g. BCL3 (Wakefield et al., 2013), ICAM1 10 
(Di et al., 2016) and VEGFA (Kim et al., 2017)), it will be important to determine how such 11 
IL6/STAT3-targeting drugs affect the IL6/STAT3 target gene program to control the breast cancer 12 
cell phenotype in the future. 13 
Interestingly, resistance to CDK4/6 inhibitors, which are now standard of care for metastatic ER+ 14 
patients, has been linked to repression of ER and activation of IL6/STAT3 signaling (Kettner et 15 
al., 2019). This suggests that the ER-independent IL6/STAT3 mechanism described here is active 16 
in CDK4/6 resistant patients supporting the rationale for exploring IL6/STAT3 inhibitors in these 17 
patients. Furthermore, given that IL6 is an adipokine that is increased in obesity (Bastard et al., 18 
2000) and both IL6 and obesity are linked to metastasis of ER+ breast cancers (Madeddu et al., 19 
2014), the IL6/STAT3 pathway is a potential driver of obesity-driven ER+ breast cancer. Our 20 
conclusions suggest that this is independent of the ER pathway and unaffected by ER targeted 21 





Previous work has shown that tumor necrosis factor  (TNF) and IL1 cytokine signaling can 1 
utilize the transcriptional activity of ER to activate target gene expression that ultimately regulates 2 
growth and metastasis (Franco et al., 2015; Stender et al., 2017). The mechanism through which 3 
IL6/STAT3 signaling controls breast cancer progression is therefore different from the 4 
mechanisms that have been described for these cytokines, since this pathway does not depend on 5 
ER function. Thus, we propose a model of paracrine signaling by cytokines in the tumor 6 
microenvironment, whereby IL6/STAT3 induces a pro-metastatic phenotype without functional 7 
convergence with the key oncogenic driver, a potential mechanism applicable for multiple cancer 8 
types associated with IL6/STAT3 signaling. 9 
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Main Figure Titles and Legends 1 
Figure 1. IL6/STAT3 signaling increases primary tumor growth and metastasis.  2 
(A) Representative H&E staining and immunohistochemistry (IHC) for phosphorylated STAT3 3 
(pSTAT3Y705) and ER in luciferase-expressing T47D primary MIND tumors expressing human 4 
IL6 or empty vector (EV). Scale bar = 50 m. (B) Growth of the primary T47D MIND tumors as 5 
determined by changes in radiance relative to day 1 after cell injection. 5 mice per condition, 17 6 
glands for EV and 15 glands for IL6. Mean of the fold change in radiance per gland is shown with 7 
error bars representing SEM. ****padj<0.0001 (two way ANOVA, Sidak’s multiple comparisons 8 
test). (C) Relative metastatic burden in mice having primary tumors expressing IL6 or EV (n=5) 9 
as measured by radiance. Error bars represent SEM. ***padj<0.001 (two-way ANOVA, Sidak’s 10 
multiple comparisons test). (D) Representative images showing radiance from micrometastases in 11 
bones and lungs used in panel C. (E,F) Kaplan-Meier (KM) plots showing the association between 12 
BCSS (E) or OS (F) and IHC staining of pSTAT3Y705 and IL6 in breast tumors from the 13 
Nottingham cohort (Ahmad et al., 2018; Aleskandarany et al., 2016). Log-rank p values are 14 
indicated for IL6+/pSTAT3+ vs all other cases. See also Figure S1. 15 
 16 
Figure 2. STAT3 associates with the ER/FOXA1 complex in response to activation by 17 
phosphorylation in cell lines and patients.  18 
(A) ER and STAT3 qPLEX-RIME in MCF7 cells in response to 30 min treatment with 19 
recombinant human IL6. Four replicates of the ER or STAT3 RIME and one pooled IgG control 20 
RIME were included in each 9plex tandem mass tags experiment. Red points, padj<0.05, 21 
qPLEXanalyzer (Papachristou et al., 2018). (B) ER qPLEX-RIME in nine patient samples, i.e. five 22 





identified in clinical breast tumors (Papachristou et al., 2018) were removed. In addition to ER 1 
(red) and STAT3 (blue), known ER-associated proteins are highlighted in light blue. The peptide 2 
coverage of STAT3 is shown in the insert. The schematic illustration was created with 3 
BioRender.com. See also Figure S2 and Table S1. 4 
 5 
Figure 3. STAT3 chromatin binding overlaps extensively with binding of ER and FOXA1 6 
in cell lines and patients. 7 
(A) ChIP-seq in T47D cells in response to 30 min IL6 treatment (n=4). Groups of binding sites are 8 
defined based on the positional overlap between pSTAT3 and ER binding sites in the IL6 9 
condition. Color bars indicate scale for normalized tag densities per 20 M subsampled reads. (B) 10 
Shared pSTAT3-ER binding sites from panel A are divided into constitutive or increased 11 
(padj<0.05, DiffBind (Stark and Brown, 2011)) ER binding sites. UCSC genome browser 12 
(http://genome.ucsc.edu, Dec. 2013 GRCh38/hg38) (Kent et al., 2002) screen shots for a 13 
representative gained and common ER binding site are shown to the right. (C) Positional overlap 14 
between ER and pSTAT3 chromatin binding based on ChIP-seq in ER+/pSTAT3+ primary breast 15 
tumors. The heatmaps show binding in the shared pSTAT3-ER sites for each patient. Color bars 16 
indicate scale for normalized tag densities per 20 M subsampled reads. The schematic illustration 17 
was created with BioRender.com. See also Figures S3 and S4. 18 
 19 
Figure 4. Shared pSTAT3-ER-FOXA1 sites control the IL6-induced gene program. 20 
(A) Left, differentially expressed genes (padj<0.05, DESeq2 (Love et al., 2014)) in response to 21 
one hour IL6 treatment of T47D cells as determined by RNA-seq (n=6). Right, significantly 22 
enriched Hallmark terms from MSigDB (Liberzon et al., 2015) in IL6-induced genes. (B) 23 





compared to an equal number of constitutively expressed genes in T47D cells. Lines illustrate the 1 
cumulative percentage of sites within a given distance from the TSS. (C) Percentage of breast 2 
cancer ATAC-seq peaks occupied by both pSTAT3 and ER or only pSTAT3 in T47D cells that 3 
are connected to IL6 target gene promoters through promoter-enhancer connections (Corces et al., 4 
2018) (Red line). The distribution of connections between the same number of random ATAC-seq 5 
peaks and IL6 target gene promoters is shown for comparison in blue (10,000 iterations to estimate 6 
the distribution of the test statistic under the null hypothesis). *Approximate random permutation 7 
p value <0.0001. (D) Identified functional promoter-enhancer links between IL6-induced genes 8 
and pSTAT3-ER occupied breast cancer ATAC-seq peaks. See also Figure S5. 9 
 10 
Figure 5. IL6/STAT3 signaling through pSTAT3-ER-FOXA1 enhancers is functionally 11 
independent of ER/FOXA1.  12 
(A) Venn diagram showing the overlap between IL6-dependent (1,282 sites) and FOXA1-13 
dependent (2,303 sites) ATAC-seq peaks (n=3). IL6-dependent sites were defined as those with 14 
padj<0.05 (DiffBind (Stark and Brown, 2011)) comparing siControl-IL6 to siControl-veh. 15 
FOXA1-dependent sites were defined as those with padj<0.05 comparing siFOXA1-IL6 to 16 
siControl-IL6. (B) ATAC-seq and ChIP-seq for pSTAT3, ER, FOXA1 and H3K27ac in IL6- and 17 
FOXA1-dependent sites from panel A (n=3-4). FOXA1 ChIP-seq is from Figure 3A. (C) 18 
Enrichment of IL6- and FOXA1-dependent sites from panel A in the vicinity of IL6-induced genes 19 
compared to constitutively expressed genes. Lines illustrate the cumulative percentage of sites 20 
within a given distance from the TSS. (D) Gene expression as reads per kb per million (RPKM) 21 
for IL6-induced genes with TSS within 50 kb of IL6-dependent ATAC-seq peaks (113 genes) in 22 





Wilcoxon test comparing veh and IL6 treatment for the different knock downs). Boxplot 1 
definitions: Center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile 2 
range; any outliers have been hidden. Notch shows the approximate 95% confidence interval for 3 
the median. (E) Regulation of IL6-induced genes (1 h treatment, padj<0.1, DESeq2 (Love et al., 4 
2014)) in STAT3-/- MCF7 cells and in response to fulvestrant treatment (100 nM for 3 h prior to 5 
the start of the IL6 treatment) in WT cells (n=4). (F) Expression of FOXA1-induced genes with 6 
TSS within 50 kb of FOXA1-dependent ATAC-seq peaks (369 genes) as in panel D. *p<10-4, 7 
**p=2.2x10-308 (two-sided Wilcoxon test comparing veh and IL6 in siControl to veh and IL6 in 8 
the different knock downs, respectively). See also Figure S6. 9 
 10 
Figure 6. IL6/STAT3 signaling is resistant to endocrine therapy, but the JAK inhibitor 11 
ruxolitinib inhibits activation of STAT3 and invasion in resistant PDX. 12 
(A) Regulation of Hallmark early estrogen responsive genes (n=200) (Liberzon et al., 2015) and 13 
IL6-induced genes (n=328 for T47D and n=67 for MCF7) in matched samples from 42 patients 14 
treated with letrozole for at least four months in the neoadjuvant setting (Selli et al., 2019). The 15 
mean regulation of 200 random genes is included for comparison with the error bar representing 16 
the standard deviation of 1,000 iterations. *p=1.8e-07 and **p< 2.2e-16  (Fisher’s exact test, two-17 
sided). The schematic illustration was created with BioRender.com. (B) Representative H&E, 18 
pSTAT3Y705 and Ki67 IHC staining for a WT ER+/PR- PDX (AB555P) (Bruna et al., 2016) explant 19 
treated with ruxolitinib (500 nM) for two days ex vivo. Scale bars = 50 m. (C) Quantification of 20 
pSTAT3Y705 and Ki67 IHC staining in the PDX explant from panel B using the Halo TM (Indica 21 
labs) Image analysis platform. Error bars represent SEM between different tumor pieces (n=9-10) 22 
from different parts of the PDX tumor cultured on the same sponge. *p=0.099, **p=1.1e-06 23 





explant from panel B. Average dots per cell for these three genes and the housekeeping gene 1 
TATA-binding protein (TBP) were determined by RNAscope in situ hybridization. Error bars 2 
represent SEM between different tumor pieces (n=7-8) from different parts of the PDX tumor 3 
cultured on the same sponge. *p= 0.098, **p=0.0074, ***p=0.00013 (Student’s t-test, two-sided). 4 
(E) Primary tumor growth of endocrine-resistant intraductal PDX in response to fulvestrant (Fulv) 5 
or ruxolitinib (Ruxo) treatment (initiated one week after injection). Points represent average 6 
growth of tumors and error bars represent SEM. n=19, 22, 22, 16 tumors from 8 mice per treatment 7 
arm. *p<0.05, ****p<0.0001 (Two way ANOVA, followed by Tukey’s multiple comparison test).  8 
Insert shows the relative fold change in radiance at endpoint. (F) Quantification of expression of 9 
protein markers in the PDX from panel E as determined by IHC. Error bars represent SEM, n=4-10 
5. (G) H&E staining and representative images of protein marker expression in adjacent sections 11 
in the PDX from panel E. (H) Quantification of Ki67 expression from panel G. Error bars represent 12 
SEM, n=4-5. (I) Quantification of tumor invasion in the mammary gland in the PDX from panel 13 
E. The invasive areas of the tumor, characterized by loss of the myoepithelial layer of the duct and 14 
tumor cell invasion into the surrounding tissue, were quantified by automated cell detection, 15 
manually curated and annotated. The percentage area of invasion relative to total tumor area 16 
(invasive and in situ) was determined. Error bars represent SEM, n=4-5. The presence of one 17 
outlier in the fulvestrant arm was identified and removed using Graphpad Prism outlier function 18 
with Q=2%. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 (One way ANOVA, followed by 19 
Tukey’s multiple comparison test).  See also Figure S7. 20 
 21 
Figure 7. Schematic model of IL6/STAT3 and ER/FOXA1 function in breast cancer. 22 
The two potent oncogenic pathways, ER/FOXA1 and IL6/STAT3, drive breast tumor growth and 23 





with BioRender.com. FHRE, Forkhead response element; ERE, Estrogen response element; 1 





STAR Methods 1 
Resource Availability 2 
Lead Contact 3 
Requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact 4 
Jason S. Carroll (jason.carroll@cruk.cam.ac.uk).  5 
 6 
Materials Availability 7 
Cell lines generated in this study are available upon request. 8 
 9 
Data and Code Availability 10 
The ChIP-seq and RNA-seq datasets generated during this study are available at Gene Expression 11 
Omnibus (GEO) with accession GSE126006. The proteomics datasets generated during this study 12 
are available at Proteomics Identification Database (PRIDE) with accession PXD012980. The 13 
code supporting the current study is available upon request. 14 
 15 
Experimental Model and Subject Details 16 
Animals 17 
Animal experiments were performed in accordance with protocol VD1865.4 approved by the 18 
Service de la Consommation et des Affaires Vétérinaires of Canton de Vaud. NOD.Cg-Prkdcscid 19 
Il2rgtm1Wjl/SzJ mice (NSG) were purchased from Charles River.  20 
Animals were housed in IVC cages – Green line – from Tecniplast®, type II long in polysulfone, 21 
with bottles in polysulfone as well (5 mice per cage). Cages were in over-pressure compared to 22 





outside of the barrier unit. Bedding was provided by Aspen Tapvei® (little squares about 4 x 4 x 1 
1 mm). Water was acidified (pH between 2.5 to 3) on resin column (Prominent® CH system) and 2 
diet was from Provimi-Kliba® (cat# 3242, irradiated). The cages were enriched with nesting 3 
material (tissues) and cardboard and wood tunnels. Housing room temperature was at 22 °C +/- 2 4 
°C, humidity 55% +/- 10%. Twelve hours light cycle, 7 am to 7 pm. 5 
 6 
Human tumors  7 
ChIP-seq 8 
Matched fresh-frozen and FFPE samples from early stage, primary, ER+ invasive breast cancers 9 
from female patients undergoing surgical resection at the Nottingham City Hospital between 1992 10 
and 1997 with high pSTAT3Y705 expression (Aleskandarany et al., 2016) were sectioned according 11 
to institutional protocols. None of these patients received neoadjuvant therapy. 12 
This study was approved by the North West – Greater Manchester Central Research Ethics 13 
Committee under the title; Nottingham Health Science Biobank (15/NW/0685). All patients 14 
provided written informed consent. All procedures performed in studies involving human 15 
participants were in accordance with the ethical standards of the institutional and/or national 16 
research committee and with the 1964 Helsinki declaration and its later amendments or comparable 17 
ethical standards. Release of data was also pseudo-anonymised as per the UK Human Tissue Act 18 
regulations. 19 
qPLEX-RIME 20 
Primary tumor material from female patients was obtained from the biobank at the Netherlands 21 
Cancer Institute and cryosectioned in 30x30 μm. Pleural effusions were collected from female 22 





Pellets were stored at -80 °C without DMSO. In brief, the cells in the pleural effusions were 1 
isolated by centrifugation, exposed to an erythrocyte lysis buffer and remaining cells were then 2 
split for formalin‐fixed and paraffin‐embedded for histological assessment/staining as well as 3 
cryo-storage as a cell pellet in eppendorf tubes kept at -80 °C until further use. H&E’s were 4 
sectioned from the FFPE blocks to assess tumor cell percentage. Pleural samples used for qPLEX-5 
RIME contained 70-90% tumor cells, as assessed by a pathologist. Available patient information 6 
is shown in Table S1.    7 
This study was performed in accordance with the institutional medical ethical guidelines. The use 8 
of anonymous or coded leftover material for scientific purposes is part of the standard treatment 9 
agreement with patients, and therefore, informed consent was not required according to Dutch law 10 
for patients not actively opting out. 11 
PDX models for explants and MIND 12 
PDX models for tumor explants were previously published with all required ethics approvals 13 
(Bruna et al., 2016). For the MIND PDX, the study of primary tumors was approved by the 14 
Commission cantonale d'éthique de la recherche sur l'être humain (CER-VD 38/15), patients 15 
signed an informed consent. Clinical information on patient age, menopausal status, primary tumor 16 
size, nodal status, histological type, ER, PR, Ki67, HER2 status, was collected from clinical charts 17 
and anonymized. 18 
 19 
Cell lines 20 
MCF7 cells (female, ATCC) were grown in DMEM (Gibco, 41966-029) supplemented with 10% 21 
fetal bovine serum (FBS – Gibco, 10500-064), 50 U/ml penicillin and 50 g/ml streptomycin 22 





grown in RPMI (Gibco, 21875-034) supplemented with 10% FBS, penicilin/streptomycin and L-1 
glutamine as for MCF7 cells. Cells were routinely genotyped by short-tandem repeat (STR) 2 
genetic profiling using the PowerPlex 16HS Cell Line panel and analyzed using the Applied 3 
Biosystems Gene Mapper ID v3.2.1 software by the external provider Genetica DNA Laboratories 4 
(LabCorp Specialty Testing Group). Cells were mycoplasma tested (MycoProbe Mycoplasma 5 
detection kit, R&D) around every major experiment and at least every six months. All cell lines 6 
were grown at 37 ºC. 7 
 8 
Method Details 9 
Mouse intraductal xenografts experiments 10 
T47D cells were subjected to lentiviral transduction with pLEX_TRC211/L2N-TurboRFP-c 11 
(Stock et al., 2016) driving both turboRFP and luciferase2 expression followed by lentiviral 12 
transduction with either empty vector or with IL6 expression vector as described below. The PDX 13 
was established from ascites effusion of a patient diagnosed with an ER+/PR+ NST stage IV cancer, 14 
that was treated with multiple lines of both chemotherapy and endocrine therapy during a period 15 
of 10 years. 16 
The cells were injected intraductally in 3 glands per mouse on average, as previously described 17 
(Sflomos et al., 2016). Briefly, 10-week-old NSG females were anesthetized by intraperitoneal 18 
injection with 10 mg/kg xylazine and 90 mg/kg ketamine (Graeub) and injected into the cleaved 19 
teat with a blunt end Hamilton syringe (cat. No. HAMI80508), specifications: 50 µl 705N, gauge 20 





Tumor growth was measured weekly on the lateral sides of the mice by IVIS Spectrum (Perkin 1 
Elmer). To assess metastatic burden, organs were carefully collected; bones were deprived of 2 
muscle to avoid any background and the ex vivo bioluminescence was measured by IVIS. 3 
Ruxolitinib (Adooq, cat# INCB018424) was prepared for dosing in 0.5% methylcellulose (400 4 
cps) (Sigma-Aldrich, cat# M0262) in water. Formulations were prepared approximately biweekly 5 
as suspensions, even distribution was achieved by sonication at 4 °C for 30 min. Vehicle and test 6 
article suspensions were administered once daily by oral gavage at a dose volume of 10 ml/kg 7 
(Shuey et al., 2016). The last dose was administered 5 h before sacrifice. 8 
Fulvestrant (cat# S1191, Selleckchem) was purchased already dissolved in 4% DMSO-castor oil 9 
solution at a concentration of 20 mg/ml. It was administered weekly by subcutaneous injection at 10 
a dose of 160 mg/kg. The last dose was administered 3 days before sacrifice. 11 
 12 
Treatment of cells 13 
Cells were treated in full media described above, rather than in media supplemented with charcoal 14 
stripped serum, to maintain full estrogenic conditions and normal growth factor and hormone 15 
signaling. This approach most accurately recapitulates the conditions in treatment naive patients. 16 
An estrogenic background is also necessary for studying ER function on chromatin in response to 17 
treatment.  18 
Unless otherwise noted, cells were treated with 20 ng/ml human recombinant IL6 (R&D systems, 19 
206-IL-200) dissolved in PBS+0.1% bovine serum albumin (BSA) by directly adding the required 20 
volume of IL6 stock solution to the media. Cells were treated for 30 min (ChIP-seq and ATAC-21 
seq) or 1 h (RNA-seq) before cell harvest. Fulvestrant (SelleckChem Cat# S1191) treatment (100 22 






Generation of MCF7 STAT3-/- by CRISPR 2 
A clone from MCF7 cells stably transfected with a luciferase/mStrawberry construct with high 3 
expression of luciferase was identified. The growth, responsiveness to anti-estrogens and STR 4 
genotype of this clone was validated to confirm that the phenotype was similar to parental MCF7 5 
cells. This provided a clonal MCF7 cell line (MCF7-luc) as a parental clone for the CRISPR-6 
mediated knock out of STAT3, which circumvented confounding factors associated with the 7 
comparison of clonal knock out cell lines and multiclonal parental cells. 8 
Four CRISPR guides were designed against Exons 3 and 4 of STAT3 (NM_139276). Sequences 9 
are available upon request. Oligos (Sigma Aldrich) were cloned into pSpCas9(BB)-2A-GFP 10 
(PX458, Addgene#48138), and constructs were transfected into the clonal MCF7-luc cell line. 11 
Three days post-transfection, GFP+ cells were FACS sorted into 6 well plates. After another eight 12 
days, mStrawberry+ cells were single cell sorted into 96 well plates by FACS and allowed to form 13 
colonies for ~3 weeks. STAT3 expression in these colonies was determined by In-Cell Western 14 
using a STAT3-specific antibody (Cell Signaling, 9139) and the CellTag 700 cellular stain (Li-15 
Cor, 926-41090) to normalize cell number. Eight putative STAT3-/- clones were expanded and the 16 
loss of STAT3 was confirmed by western blotting using a different STAT3 antibody (Cell 17 
Signaling, 4904). The frameshift mutations induced by CRISPR were identified by targeted next 18 
generation sequencing (NGS) of an amplicon containing the guide RNA target site. The two most 19 
likely off-target sites for all but one guide, which had no predicted off-target sites (Hsu et al., 20 
2013), were tested for off-target editing using the same NGS approach as described above. Two 21 
clones with heterozygotic frameshift mutations and no off-target mutations were used for 22 





Sanger sequencing. The STAT3-/- clones were STR genotyped and mycoplasma tested as described 1 
under “Cell lines”. 2 
 3 
siRNA-mediated knock down 4 
T47D cells were transfected with ON-TARGETplus SMARTPools (Dharmacon) targeting STAT3 5 
(L-003544-00-0020), ER (L-003401-00-0020) or FOXA1 (L-010319-00-0020) using 6 
Lipofectamine RNAiMAX (Invitrogen, 13778-150). A non-targeting pool (D-001810-10-20) was 7 
used as a control. The media was changed 24 h after transfection, and cells were treated for one 8 
hour with IL6 48 h after transfection. 9 
 10 
Ectopic expression of luciferase and IL6 11 
T47D cells were infected with lentivirus driving expression of luciferase2 and turboRFP 12 
(pLEX_TRC211/L2N-TurboRFP-c) (Stock et al., 2016) followed by FACS sorting to obtain a 13 
population of cells expressing high levels of turboRFP. These cells were then infected with 14 
lentivirus encoding human IL6 (EX-A0301-Lv197) or empty vector (EX-NEG-Lv197) followed 15 
by selection with blasticidin (20 g/ml, Gibco, A11139-03) until non-infected controls cells had 16 
all died. Expression and release of IL6 into the media was validated by ELISA (see Figure S1A) 17 
and activation of STAT3 by phosphorylation downstream of IL6 signaling was validated by 18 
western blot (see Figure S1B). The T47D-luc cells expressing IL6 or empty vector were genotyped 19 
and mycoplasma tested as described under “Cell lines”. 20 
 21 





Fresh WT ER+/PR- PDX tumors (STG335 and AB555P) (Bruna et al., 2016) were cut into small 1 
(2 mm3) pieces and placed on Spongostan gelatin dental sponges (Ferrosan Medical Devices, 2 
MS0005) soaked in explant media (RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine 3 
(Gibco, 25030), 10 g/ml hydrocortisone (Sigma, H0888), 1xinsulin-transferrin-selenium 4 
supplement (Sigma, I3146) and 1xAntibiotic Antimycotic Solution (Sigma, A5955)). For STG335 5 
(Figure S7E,F), media was replaced after 24 h with media containing 50 ng/ml IL6 (R&D systems, 6 
206-IL-200) and 500 nM ruxolitinib (Selleckchem, S1378) as indicated for two days. Treated 7 
media was refreshed every day and two hours before fixation in 10% neutral-buffered formalin for 8 
24 h. For AB555P (Figure 6B-D), tumor pieces were placed on sponges soaked in media with or 9 
without ruxolitinib (500 nM) and incubated for two days without media change before fixation in 10 
10% neutral-buffered formalin. Tumor sections were subjected to staining with hematoxylin and 11 
eosin (H&E), pSTAT3Y705 IHC staining (Cell Signaling, 9145), Ki67 IHC staining (Dako, M7240) 12 
or RNAscope in situ hybridization.  13 
 14 
IL6 ELISA 15 
106 T47D-luc cells expressing IL6 or empty vector were seeded in a 10 cm dish. After three days 16 
of culture, the media was harvested, and the IL6 levels were determined by ELISA (EH2IL6, 17 
Thermo Fisher Scientific) according to the manufacturer’s instructions. 18 
 19 
qPLEX-RIME 20 
Cell lines 21 
qPLEX-RIME on cell lines was performed essentially as described previously (Papachristou et al., 22 





disuccinimidyl glutarate (DSG) for 20 min followed by 1% formaldehyde for 10 min before 1 
quenching in 0.1 M glycine for 10 min. Cells were washed twice in cold PBS and harvested in 2 
cold PBS containing protease (Roche, Complete, 05056489001) and Halt phosphatase inhibitors 3 
(Thermo Scientific, 78427). Crosslinked cells were incubated at 4 C with LB1 (50 mM Hepes–4 
KOH pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% Glycerol, 0.5% NP-40/Igepal CA-630, 0.25% 5 
Triton X-100) for 10 min followed by 5 min in LB2 (10 mM Tris–HCL pH8.0, 200 mM NaCl, 1 6 
mM EDTA, 0.5 mM EGTA) before resuspending in LB3 (10 mM Tris–HCl pH 8, 100 mM NaCl, 7 
1 mM EDTA, 0.5 mM EGTA, 0.1% Na–Deoxycholate, 0.5% N-lauroylsarcosine). Chromatin was 8 
sonicated using the Bioruptor Plus (Diagenode) for 15 min (30 sec on/30 sec off) to generate DNA 9 
fragments of around 100-800 bp. Chromatin was immunoprecipitated overnight using protein A 10 
(Invitrogen, used for rabbit antibodies) or protein G (Invitrogen, used for goat antibodies) 11 
dynabeads with specific antibodies against ER (Santa-Cruz, sc-543 or mix of abcam, ab3575 and 12 
Millipore, 06-935), STAT3 (Santa Cruz, sc-482), pSTAT3Y705 (Cell Signaling, 9145), FOXA1 13 
(abcam, ab5089) or H3K27ac (abcam, ab4729). Beads were washed 10 times in RIPA buffer (50 14 
mM HEPES pH 7.6, 1 mM EDTA, 0.7% Na-deoxycholate, 1% NP-40, 0.5 M LiCl) followed by 15 
two washes in AMBIC (100 mM ammonium hydrogen carbonate). Washed beads were frozen at 16 
-20 C. 17 
 18 
LC-MS analysis and data processing 19 
For the proteomic analysis, samples were prepared as previously described (Papachristou et al., 20 
2018). Briefly, the bound proteins were digested on the beads overnight with the addition of trypsin 21 
at final concentration 15 ng/ul (Pierce) followed by a second digestion step the next day for 4 h. 22 





Scientific) followed by fractionation using Reversed-Phase spin columns at high pH (Pierce 1 
#84868). LC-MS analysis was performed on the Dionex Ultimate 3000 UHPLC system coupled 2 
with the nano-ESI Fusion Lumos (Thermo Scientific) mass spectrometer. The Lumos was operated 3 
in a data-dependent mode for both the MS2 and the SPS-MS3 methods. Precursors were selected 4 
at 120k resolution and the collision energy was set at 35%. Peptides were isolated in the quadrupole 5 
with isolation window 0.7 Th. The top 10 most intense fragments were selected for Synchronous 6 
Precursor Selection (SPS) HCD-MS3 analysis with MS2 isolation window 2.0 Th. The HCD 7 
collision energy was set at 55% and the detection was performed with Orbitrap resolution 50k or 8 
60k. The raw data were processed with the SequestHT search engine in Proteome Discoverer 2.1. 9 
The SequestHT node included the following parameters: Precursor Mass Tolerance 20ppm, 10 
Fragment Mass Tolerance 0.5 Da, Dynamic Modifications were Oxidation of M (+15.995 Da), 11 
Deamidation of N/Q (+0.984 Da) and Static Modifications were TMT6plex at any N-Terminus/K 12 
(+229.163 Da). Only unique peptides were used for quantification and the consensus workflow 13 
included calculation of TMT signal-to-noise. The percolator node with decoy database search was 14 
used to estimate the confidence level for peptide identifications. The peptide intensities were 15 
normalized using median scaling and aggregated (by summing) to protein intensities. qPLEX-16 
RIME data was analyzed by the qPLEXanalyzer (10.18129/B9.bioc.qPLEXanalyzer) 17 
(Papachristou et al., 2018) to identify significant changes in protein interactions using limma based 18 
analysis (Ritchie et al., 2015). Data was visualized using ggplot2 (Wickham, 2016) in R. 19 
 20 
Clinical samples 21 
qPLEX-RIME on tumor material was performed essentially as described previously (Papachristou 22 





into 30 m sections, crosslinked by 2 mM DSG for 45 min total together with 1% formaldehyde 1 
for the last 20 min and quenched by 0.1 M glycine for 10 min at room temperature. After two 2 
washes in cold PBS, crosslinked sections were resuspended in LB3 and sonicated using a probe 3 
sonicator (Fisher Scientific) until most DNA fragments were 100-800 bp. Chromatin was 4 
immunoprecipitated, washed and processed for mass spectrometry analysis as described for cell 5 
lines. Specific ER-associated proteins were identified by removing non-specific proteins 6 
previously identified by ER/IgG qPLEX-RIME in human breast tumors (Papachristou et al., 2018). 7 
Non-specific proteins were defined as those with padj>0.05 or Log2 fold change 1 comparing 8 
ER and IgG samples. However, even with this filtering step a few unspecific proteins with high 9 
intensity remain. These include keratins, fibrinogen, ribonucleoproteins and a couple of abundant 10 
metabolic enzymes. 11 
 12 
ChIP-seq 13 
Cell lines and tumors 14 
ChIP-seq was performed on three to four independent biological replicates. Chromatin was 15 
prepared from both cell lines/tumors and immunoprecipitated as described for qPLEX-RIME 16 
above. After washing of the beads, chromatin was eluted and decrosslinked by incubating over 17 
night at 65 C in elution buffer (50 mM TrisHCl pH8, 10 mM EDTA, 1% SDS). Samples were 18 
treated with RNase A (20 ng/ml) for 30 min-1 h followed by proteinase K (200 ng/ml) for 1-2 h 19 
before DNA was purified by phenol-chloroform extraction. Purified DNA was subjected to library 20 
preparation using the SMARTer ThruPLEX® DNA-Seq Kit (TaKaRa, R400676) and DNA HT 21 
Dual Index Kit – 96N Set A (TaKaRa, R400660) followed by Illumina next generation sequencing 22 






50 bp single-end reads were mapped to hg38 genome using bowtie2 2.2.6 (Langmead and 2 
Salzberg, 2012). Aligned reads with mapping quality less than 5 were filtered out. The read 3 
alignments from all replicates were combined into single library and peaks were called with 4 
MACS2 version 2.1.1.2016 (Zhang et al., 2008) using input sequences as a background control. 5 
The peaks that absorbed statistically significant tag density from all replicates were selected for 6 
downstream analysis. MEME version 4.9.1 (Bailey et al., 2009) was used to detect known and 7 
discover novel binding motifs amongst tag-enriched sequences. For visualizing tag density and 8 
signal distribution heatmap the read coverage in a window of +/- 2.5 or 5 kb region flanking the 9 
peak midpoint was generated using a bin size of 1/100 of the window length. Differential binding 10 
analysis (Diffbind) was performed as described previously (Stark and Brown, 2011). Motif 11 
matrices for ER, FOXA1 and STAT3 from the JASPAR database (Mathelier et al., 2016) were 12 
used for motif enrichment analyses in ChIP-seq peaks relative to open chromatin as previously 13 
determined by ATAC-seq (Toska et al., 2017). 14 
 15 
RNA-seq 16 
Total RNA was purified using RNeasy kit (Qiagen, 74106) and mRNA libraries were prepared 17 
using the TruSeq stranded mRNA library preparation kit (Illumina, cat#20020595) and IDT for 18 
Illumina – TruSeq RNA UD Indexes (cat# 20022371). Samples were subjected to Illumina next 19 
generation sequencing to reach around 30 M reads per sample. 20 
Analysis 21 
50 bp single-end reads were aligned to the human genome version GRCh37 using STAR version 22 





binomial distribution using the DESeq2 package (Love et al., 2014) 1 
(https://bioconductor.org/packages/release/bioc/html/DESeq2.html) version 1.14.1 in R. Heatmap 2 
visualisation, clustering and various plotting functions were used from statistical and bioinfo 3 
modules in MATLAB framework (https://www.mathworks.com). 4 
 5 
ATAC-sequencing 6 
T47D cells were transfected with siRNA targeting FOXA1 or control siRNA as described above 7 
(see “siRNA-mediated knock down”). After two days of knock down, cells were treated with IL6 8 
(20 ng/ml) for 30 min before processing cells for ATAC-seq. Omni-ATAC-sequencing was 9 
performed as previously described (Corces et al., 2017). ATAC-seq resuspension buffer (RSB) 10 
was prepared as follows: For 50 ml of the buffer, 500 µl 1M Tris-HCl pH 7.4, 100 µl 5M NaCl, 11 
150 µl 1M MgCl2, and 49.25 ml sterile water were added. 50 µl cold ATAC-RSB containing 0.1% 12 
NP40, 0.1% Tween-20 and 0.01% Digitonin (Promega cat# G9441) was added to 50,000 viable 13 
cells and pipetted up and down three times. The cells were incubated on ice for 3 minutes to lyse 14 
the cells and washed out with 1 ml of cold ATAC-RSB containing 0.1% Tween-20, but without 15 
NP40 and digitonin. The tube was inverted three times to mix. The nuclei were pelleted at 500xg 16 
for 10 min at 4 ºC in a fixed angle centrifuge. The pellet was resuspended in 50 µl transposition 17 
mix (25 µl 2xTagment buffer, 2.5 µl transposase (100 nM final, Illumina Tagment DNA Enzyme 18 
and Buffer Small Kit, Cat. No. 20034197), 16.5 µl PBS, 0.5 µl 1% digitonin, 0.5 µl 10% Tween-19 
20, 5 µl H2O) and the reaction was incubated at 37 ºC for 30 min in a thermomixer with 1,000 20 
RPM mixing. Zymo DNA Clean and Concentrator-5 Kit (cat# D4014) was used to clean up the 21 
reaction and DNA was eluted in 21 µl elution buffer and stored at -20 °C until amplification. 20 22 





using 1 µl of i5 primer, 1 µl of i7 primer, 25 µl 2xQ5 HotStart NEBNext master mix (M0494L), 1 
and 20 µl transposed/cleaned-up sample. Thermocycler conditions (72 ºC for 5 min, 98 ºC for 30 2 
sec, followed by 5 cycles of [ 98 ºC for 10 sec, 63 ºC for 30 sec, 72 ºC for 1 min] then hold at 4 3 
ºC. Using 5 µl (10%) of the pre-amplified mixture, 15 µl qPCR was run to determine the number 4 
of additional cycles needed as follows: 3.85 µl sterile water, 0.2 µl Nextera XT Index kit (24 5 
indexes, FC-131-1001) i5 primer, 0.2 µl i7 primer, 0.75 µl 20x EvaGreen (in DMSO), 5 µl 6 
2xNEBNext master mix, 5 µl pre-amplified sample. Cycling conditions: 98 ºC for 30 sec, followed 7 
by 20 cycles of [98 ºC for 10 sec, 63 ºC for 30 sec, 72 ºC for 1 min]. After qPCR amplification, 8 
the amplification profiles were assessed to determine the required number of additional cycles to 9 
amplify. Final amplification and clean-up was performed on the remaining 45 µl of the pre-10 
amplified DNA. Samples were size selected and purified using Ampure XP beads. Next generation 11 
sequencing was performed using Illumina Novaseq 6000 with SP flow cell system with 50 bp 12 
paired end reads to get around 40 M reads per sample. 13 
 14 
ChIP-seq enrichment near regulated genes 15 
The cumulative numbers of ChIP-Seq binding sites located within the 10 kb linear scale from the 16 
TSS of significantly up-regulated genes were determined. As a background control, binding sites 17 
near an equal number of random constantly expressed genes revealed by the RNA-seq analyses 18 
were tested in 100 permutations. Fraction of binding sites near these groups of genes were then 19 
visualized as curves including the standard deviation for the random constitutively expressed 20 
control genes as error bars. 21 
 22 





Table S2 and S7 from (Corces et al., 2018) were downloaded. They identify open chromatin 1 
regions, as determined by ATAC-seq, and functional links between distal regulatory open 2 
chromatin regions and their target genes in TCGA tumors, respectively. Briefly, these promoter-3 
enhancer links were established by correlating changes in accessibility to changes in expression of 4 
genes within 500 kb using 373 tumor samples with matched ATAC-seq and RNA-seq data (Corces 5 
et al., 2018).  6 
All the ATAC-seq peaks from TCGA breast cancer samples that had a positional overlap with a 7 
pSTAT3-ER binding site from T47D cells or patient samples were identified by GenomicRanges 8 
(Lawrence et al., 2013) in R (R Core Team, 2020). They were functionally linked to their target 9 
genes using the pan-cancer links table (Corces et al., 2018). The promoter-enhancer links between 10 
pSTAT3-ER occupied breast cancer ATAC-seq peaks and IL6-induced genes from T47D cells 11 
were compared to the links of random ATAC-seq peaks using 1,000 iterations to show that 12 
pSTAT3-ER sites are functionally linked to IL6-induced genes more than expected by chance. 13 
Circlize (Gu et al., 2014) was used to visualize these links in a circular plot. 14 
 15 
eQTL analyses 16 
eQTL (GTEx_Analysis_v8_eQTL.tar) were downloaded from the GTEx portal (11/14/2019). 17 
eQTL linked to expression of genes significantly (padj<0.05) induced by IL6 in T47D cells (4,756 18 
eQTL linked to 78 out of the 328 IL6-induced genes) were identified, and the number of binding 19 
sites overlapping at least one eQTL was determined by the GenomicRanges package (Lawrence 20 
et al., 2013) in R (R Core Team, 2020). The overlap between the same set of binding sites and 21 





included as control (1,000 iterations to the estimate the distribution of the test statistic under the 1 
null hypothesis). 2 
 3 
Proximity ligation assay 4 
Cells were fixed and permeabilized by the addition of ice-cold methanol (−20 °C) for 3 min 5 
followed by three washing steps with cold PBS. PLA was carried out according to manufacturer’s 6 
instructions (Sigma Aldrich, #DUO92007). The following primary antibodies were used for the 7 
PLA assay: ERα (sc-8002, 1:200), STAT3 (sc-482, 1:200), pSTAT3Y705 (Cell Signaling, 9131, 8 
1:200) and the incubation on the coverslips was performed for 1 h at 37 °C. The secondary 9 
proximity probes (Sigma Aldrich, anti-Rabbit-PLUS, #DUO92002 and anti-Mouse-MINUS, 10 
#DUO92004) were incubated for 1 h at 37 °C. The Leica DFC340FX microscope was used and 11 
images were captured with Leica Imaging software. Raw TIFF images were opened in FIJI version 12 
2.0.0-rc-69/1.52p. Channels were split into RGB using Image/Colour/Split Channels function. The 13 
green channel was discarded to remove background as it can cross bleed into the blue channel. 14 
Channels were remerged using only red and blue channels corresponding to DAPI and PLA 15 
staining. Brightness and contrast were adjusted identically for all images within each experiment. 16 
This adjustment was performed individually for the red and blue channels. DAPI and PLA 17 
fluorescence were captured at high resolution for a total of 8 separate observation fields. Cell 18 
numeration and PLA labelling were carried out using ImageJ software 19 
(https://imagej.net/Welcome). Cells and red PLA dots were counted using the ‘Analyze Particles’ 20 
function. For each condition at least 200 cells were imaged and analyzed. Then, the average 21 
number of spots per nucleus was calculated. All statistical analyses were carried out by performing 22 






Western blot 2 
Cells were washed twice in cold PBS and harvested in RIPA buffer (Pierce, 89901). Whole cell 3 
extract was sonicated using the Bioruptor Plus (Diagenode) for 2 min (30 sec on/30 sec off) to 4 
degrade the DNA, quantified by Direct detect Spectrometer (Millipore) and run on NuPAGE 4-5 
12% bis-Tris gels (Invitrogen). Proteins were transferred to nitrocellulose membranes by iBlot2 6 
(Invitrogen), and the membrane was then blocked by Odyssey TBS blocking solution (Li-Cor, 7 
927-50000) and incubated with antibody over night at 4 C. After washing, the membrane was 8 
then incubated with appropriate secondary antibodies (Li-Cor) and developed using the Odyssey 9 
CLx Imaging System (Li-Cor). Primary antibodies: ER (Novocastra, NCL-L-ER-6F11), STAT3 10 
(Santa Cruz, sc-482), pSTAT3Y705 (Cell Signaling, 9145), FOXA1 (Abcam, ab23738), beta-actin 11 
(Cell Signaling, 4970; Sigma, A5441). Secondary antibodies: Goat anti-rabbit (926-32211, 926-12 
68071), goat anti-mouse (926-32210, 926-68070), donkey anti-goat (926-32214). 13 
 14 
IHC on T47D-IL6 tumors and PDX explants 15 
IHC was run on Leica’s Polymer Refine Detection System (DS9800) using modified versions of 16 
their standard template on the automated Bond-III platform. De-waxing and re-hydration prior to 17 
IHC were done on the automated Leica ST5020, as was the post-IHC de-hydration and clearing. 18 
Antigen retrieval was performed in a sodium citrate buffer (pSTAT3Y705 and ER) and Tris-EDTA 19 
buffer (Ki67) at 100 C for 20 min (pSTAT3) or 30 min (ER and Ki67). Primary antibodies against 20 
the following proteins were used: pSTAT3Y705 (Cell Signaling, 9145, 1:25 dilution), ER 21 
(Novocastra, NCL-ER-6F11/2, 1.071 g/ml) and Ki67 (Dako, M7240, 1:400 dilution). Since the 22 





IgG blocking solution (Vector, MKB-2213) prior to incubation with the Ki67 antibody. Slides 1 
were incubated with primary antibody for 60 min (pSTAT3) or 15 min (ER and Ki67) at room 2 
temperature. DAB Enhancer was used for all antibodies (Leica, AR9432). Sections were mounted 3 
on Leica’s coverslipper (CV5030), and the slides were imaged on the Aperio AT2 (Leica 4 
Biosystems) to create whole slide images. Images were captured at 20x magnification, with a 5 
resolution of 0.5 microns per pixel. Whole slide images were imported into the Halo TM (Indica 6 
labs) Image analysis platform. Annotations for tumor were selected and percentage of marker-7 
positive cells was quantified using the Indica Labs Multiplex IHC v1.2 module. 8 
 9 
IHC on PDX MIND model, Figure 6 and S7  10 
IHC staining 11 
Five tumors per treatment arm were fixed with PFA and paraffin embedded. Sections were cut, 12 
dewaxed, rehydrated and subsequently stained with antibodies on Ventana (Roche) using the fully 13 
automated Ventana Discovery ULTRA (Roche Diagnostics, Rotkreuz, Switzerland) with Ventana 14 
solutions. Paraffin sections were pretreated with heat using standard condition (40 min) CC1 15 
solution. The primary antibody was applied and incubated for specific time (listed below). After 16 
incubation with a rabbit Impress HRP antibody (Vector laboratories), chromogenic revelation was 17 
performed with ChromoMap DAB kit (Roche Diagnostics, Rotkreuz, Switzerland). IHC staining 18 
for pSTAT3Y705 was done as described above for the T47D-IL6 model. 19 
Protein REF Dilution Incubation time Supplier 
ER BRB053 Ready to use 16 min Zytomed systems 
PR 790-2223 Ready to use 32 min Ventana 






IHC quantifications 1 
The slides were scanned with Olympus VS120-L100 slide scanner using a 20x/0.75 objective 2 
connected to a Pike F505 C Color camera. Images were loaded into QuPath (Bankhead et al., 2017) 3 
using the BioFormats Extension (https://github.com/qupath/qupath-bioformats-extension) and 4 
tumor cell regions were identified using a custom script. In short, the RGB images were converted 5 
to HSB (Hue Saturation Brightness), and the Brightness image was used to detect the tissue 6 
regions. 7 
A median filter of radius 3 pixels was applied, followed by ImageJ's Triangle auto-threshold 8 
method [https://imagej.net/Auto_Threshold#Triangle]. Only regions larger than 1e4 square 9 
microns were kept for analysis. 10 
The regions were then manually curated to ensure accurate detection of the tissue of interest and 11 
to define in situ versus invasive foci. Individual cells on each region were segmented using 12 
QuPath’s built-in Watershed Cell Detection algorithm parameters as follows. Color deconvolution 13 
stains: hematoxylin (0.56273 0.71108 0.42155), DAB (0.32201 0.61392 0.7207). Brightfield 14 
image detection on optical density sum: pixel size 0.2 microns. Nucleus parameters in microns: 15 
background radius 8.0, median radius 0.0, sigma 1.5, minimum area 10.0, maximum area 400.0. 16 
Intensity and cell parameters: threshold 0.05, maximum background intensity 2.0, watershed 17 
process, include nuclei, smooth boundaries, make measurements, threshold compartment DAB 18 
OD mean, threshold positive 0.15. The number of positive cells was counted, and the average 19 
values were then plotted. The invasive versus in situ area was quantified for each tumor analyzed. 20 
 21 





Detection of Human TBP, MYC, ELF3 and BCL3 mRNA was performed on FFPE sections using 1 
Advanced Cell Diagnostics (ACD) RNAscope® 2.5 LS Reagent Kit-RED (Cat No. 322150), 2 
RNAscope® 2.5 LS Probe- Hs-TBP (Cat No. 314298), RNAscope® LS 2.5 Probe- Hs-MYC (Cat 3 
No. 311768), RNAscope® LS 2.5 Probe- Hs-ELF3 (Cat No. 416408), and RNAscope® LS 2.5 4 
Probe- Hs-BCL3 (Cat No. 417608). Negative controls were performed using the RNAscope® 2.5 5 
LS Negative Control Probe - DapB (Cat No. 312038). Briefly, sections were cut at 3 µm thick, 6 
baked for 1 h at 60 ºC before loading onto a Bond RX instrument (Leica Biosystems). Slides were 7 
deparaffinised and rehydrated on board before pre-treatments using Epitope Retrieval Solution 2 8 
(Cat No. AR9640, Leica Biosystems) at 95 °C for 10 min, and ACD Enzyme from the LS Reagent 9 
kit at 40 ºC for 10 min. Probe hybridization and signal amplification was performed according to 10 
manufacturer’s instructions. Fast red detection of human TBP, MYC, ELF3, BCL3 mRNA was 11 
performed on the Bond Rx using the Bond Polymer Refine Red Detection Kit (Leica Biosystems, 12 
Cat No. DS9390) according to ACD protocol. Slides were then removed from the Bond Rx and 13 
were heated at 60 ºC for 1 h, dipped in Xylene and mounted using EcoMount Mounting Medium 14 
(Biocare Medical, CA, USA. Cat No. EM897L). 15 
The slides were imaged on the Aperio AT2 (Leica Biosystems) to create whole slide images. 16 
Images were captured at 40x magnification, with a resolution of 0.25 microns per pixel. Whole 17 
slide images were imported into the Halo TM (Indica labs) Image analysis platform. Annotations 18 
for tumor were selected and the surface area and intensity of positive staining for each annotation 19 
was quantified using the Indica Labs – Area Quantification FL v 1.0 positive pixel counting 20 
algorithm. The average number of probe copies per cell were measured using the Indica Labs – 21 






IL6/pSTAT3Y705 and breast cancer outcome 1 
Integrative IHC analysis of pSTAT3Y705 and IL6 expression was performed using a combined 2 
cohort of N=2,497 patients with primary, stage I-III breast cancer treated at a single institution in 3 
Nottingham. Within the combined cohort, pSTAT3 and IL6 expression was assessed by IHC using 4 
tissue microarrays of n=1,270 and n=1,380 cases respectively, as previously described (Ahmad et 5 
al., 2018; Aleskandarany et al., 2016). From the combined cohort, Kaplan-Meier (KM) plots of 6 
OS and BCSS were stratified by ER, IL6 and pSTAT3 status and statistical comparisons were 7 
performed using log-rank tests as indicated in the relevant figure legends using SPSS Statistics 8 
(ver26). Multivariate analysis of pSTAT3 status with clinical biomarkers (ER, PR, HER2 and Ki67 9 
status) was performed using Cox regression in SPSS Statistics. Plots of univariate and multivariate 10 
analyses were prepared using GraphPad Prism (ver7). 11 
 12 
Quantification and Statistical Analyses 13 
Two way ANOVA tests were used to determine significant differences in the size of the primary 14 
and metastatic tumors in the MIND experiments, expression of protein markers as determined by 15 
IHC and invasion (Figure 1B,C and S1E; 6E,F,H,I; S7G). The p values and n are shown in the 16 
legends. p values for KM plots showing the association between pSTAT3Y705 and IL6 IHC staining 17 
and BCSS/OS was determined by log-rank test using SPSS Statistics, ver26 (Figure 1E,F and 18 
Figure S1G,H). Univariate and multivariate analyses were performed using Cox regression in 19 
SPSS Statistics (Figure S7A,B). Significant differences in RNA-seq, ChIP-seq and ATAC-seq data 20 
(corrected for multiple testing) were determined using DEseq2 (RNA-seq) (Love et al., 2014) and 21 
DiffBind (ChIP-seq and ATAC-seq) (Stark and Brown, 2011), respectively. padj and n values for 22 





RIME were determined by qPLEXanalyzer (10.18129/B9.bioc.qPLEXanalyzer) (Papachristou et 1 
al., 2018). padj and n values are indicated in the legend for Figure 2A. In two analyses, an 2 
approximate random permutation p value was determined by comparing to an estimation of the 3 
distribution of the test statistic under the null hypothesis: 1) To determine whether the percentage 4 
of binding sites connected to IL6 target gene promoters was significantly different from random 5 
sites (Fig 4C and Figure S5C), and 2) to determine whether the overlap between pSTAT3 and ER 6 
binding and eQTLs linked to IL6 target genes was significantly different from the overlap with 7 
eQTLs linked to the same number of random expressed genes (Figure S5D). p values are indicated 8 
in the relevant figure legends. p values for the differences in the proportions of ER and IL6/STAT3 9 
target genes repressed by aromatase inhibitor treatment in patients (Figure 6A and S7C) were 10 
determined by two-sided Fisher’s exact tests and indicated in the relevant figure legends. p values 11 
for quantitative difference in PLA in response to IL6/fulvestrant and staining by IHC and 12 
RNAscope in situ hybridization in tumor explants were determined by two-sided Student’s t-test. 13 
p and n values are indicated in the relevant figure legends. Student’s t-test and Wilcoxon test were 14 
used for specific comparison throughout the manuscript with p values indicated in the relevant 15 
legends. 16 
 17 
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Figure S1. Ectopic expression of human IL6 in T47D cells activates STAT3 by Y705 
phosphorylation and induces in vivo growth and metastasis, Related to Figure 1.  
(A) Human IL6 levels in the media used for growing luciferase-expressing T47D cells expressing 
human IL6 or empty vector (EV) were determined by ELISA. Results are representative of two 
independent experiments, and error bars show standard deviations based on three technical replicates 
of the ELISA. *p=0.00052 (Student’s t-test, two-sided). (B) Western blot showing phosphorylation 
of STAT3 at Y705 in luciferase-expressing T47D cells expressing IL6, but not in cells infected with 
empty vector (EV). Actin is used as a loading control. Representative of two independent biological 
replicates. (C) Modified H-score for pSTAT3Y705 in MIND samples from luciferase-expressing T47D 
cells expressing empty vector (EV) or IL6 (four mice from each group). Due to the fact that 
Supplemental Text and Figures Click here to access/download;Supplemental Text and
Figures;CancerCell_revised_Supplementary_Data_FinalRevisi
phosphorylation of STAT3 is dictated by the tumor microenvironment, each tumor area was 
quantified separately by a histopathologist and visualized as a point in the boxplot. *p=1.6e-12 (two-
sided Wilcoxon test). Boxplot definitions: Center line, median; box limits, upper and lower quartiles; 
whiskers, 1.5x interquartile range; points, separate tumor areas. (D) Modified H-scores from 
pSTAT3Y705 IHC (Cell Signaling, 9145) of tumor foci (n=85 from four mice, see panel C) from the 
T47D-IL6 MIND tumors were compared to modified pSTAT3Y705 H-scores (Ab76315) from ER+ 
patients (n=103) (Aleskandarany et al., 2016). Non-significant (ns) p=0.058 was determined by two-
sided Wilcoxon test. Boxplot definitions: Center line, median; box limits, upper and lower quartiles; 
whiskers, 1.5x interquartile range; any outliers have been hidden. (E) Growth of primary T47D 
MIND tumors expressing empty vector (EV) or IL6 as determined by changes in radiance relative to 
day 7 after cell injection. 10 mice per condition, 23 glands for EV and 24 glands for IL6. Mean of the 
fold change in radiance per gland is shown with error bars representing SEM. ****p<0.0001 (two 
way ANOVA, Sidak’s multiple comparisons test). (F) Relative combined metastatic burden for all 
metastatic sites, i.e. bone, lung, liver and brain, in the T47D-IL6 MIND model (n=60 organs from 15 
mice per condition). Metastatic burden in individual organs is shown in Figure 1C. *p=0.016 (Mann-
Whitney test). (G,H) Kaplan-Meier (KM) plots showing the association between BCSS (G) or OS 
(H) and IHC staining of pSTAT3Y705 and IL6 in ER+ breast tumors from the Nottingham cohort 
(Ahmad et al., 2018; Aleskandarany et al., 2016). Log-rank p values are indicated for 





Figure S2. Western blot, PLA and qPLEX-RIME in cell lines and patient material, Related to 
Figure 2.  
(A) Western blot showing phosphorylation of STAT3 at Y705 in response to 30 min IL6 treatment 
in MCF7 cells. Representative of more than four independent biological replicates. (B) Peptide 
coverage of ER and STAT3 in the qPLEX-RIME experiments in MCF7 cells (top and middle) and 
clinical samples (bottom). See Figure 2 for more details. The schematic illustration was created with 
BioRender.com. (C) Intensity of the ER peptide phosphorylated on serine 167 in ER qPLEX-RIME 
(see Figure 2A for more details). Errors bars represent standard deviation of four independent 
biological replicates. p value was determined by Student’s t-test, two-sided. (D) PLA of ER/STAT3 
and ER/pSTAT3Y705 in MCF7 cells treated with vehicle (veh) or IL6 (30 min) following three hours 
of veh or fulvestrant treatment (100 nM). Top, representative images from two independent PLA 
experiments. Brightness and contrast have been adjusted identically for all images within each 
experiment. This adjustment was performed individually for the red and blue channels. Bottom, bar 
plots showing quantification of the PLA signal. Error bars represent standard deviations. *p<0.01, 
**p<0.001, ***p<0.0001 (Student’s t-test, two-sided). (E) Comparison of protein intensity in ER+ 
primary tumors and pleural effusions from ER qPLEX-RIME data. ER and STAT3 are highlighted 
in red and blue, respectively. See Figure 2B for more details. 
 
  
Table S1. Clinical information for the patients whose tumors were used for ER qPLEX-
RIME, Related to Figure 2. 
Patient   ER PR Type Hormonal Treatment 
1 + + Ductal/grade 2 None 




Treatment info is missing  
3 + + Ductal/grade 2 None 
4 + + Ductal/grade2 None 
5 + + Ductal/grade 1 None 
6 + Not 
stained 
for PR 
Pleural effusion Received adjuvant hormonal therapy  
7 + - Pleural effusion Received adjuvant hormonal therapy 
8 + Not 
stained 
for PR 
Pleural effusion Received adjuvant hormonal therapy  




Figure S3. pSTAT3, STAT3, ER, and FOXA1 ChIP-seq in T47D cells, Related to Figure 3.  
(A) Western blot showing phosphorylation of STAT3 at Y705 in response to 30 min IL6 treatment 
in T47D cells. Representative of four independent biological replicates. (B) Screen shots from the 
UCSC genome browser (http://genome.ucsc.edu, Dec. 2013 GRCh38/hg38) (Kent et al., 2002) 
showing binding of pSTAT3Y705 and total STAT3 as determined by ChIP-seq in response to 30 min 
IL6 treatment in T47D cells. (C) Venn diagram showing the positional overlap of pSTAT3Y705 and 
ER binding in T47D cells in response to 30 min IL6 treatment as determined by ChIP-seq (n=4). (D) 
Analysis of motif enrichment in ER-pSTAT3 binding sites from Figure 3A,B was performed using 
ER, FOXA1 and STAT3 motif matrices from the Jaspar database (Mathelier et al., 2016). The 
enrichment was calculated as the number of motif instances in each group of sites relative to the 




Figure S4. pSTAT3, STAT3, ER and FOXA1 ChIP-seq in MCF7 cells, Related to Figure 3.  
(A) Venn diagram showing positional overlap of pSTAT3Y705 and ER binding in MCF7 cells upon 
30 min stimulation with IL6 as determined by ChIP-seq (n=4). (B) Heatmap showing the ChIP-seq 
intensity for pSTAT3Y705, total STAT3, ER and FOXA1 at the binding sites defined in panel A in 
vehicle (Veh) control conditions and upon treatment with IL6. Color bars indicate scale for 





Figure S5. pSTAT3-ER binding sites are functionally connected to IL6-activated genes, Related 
to Figure 4.  
(A) Differentially expressed genes (padj<0.1, DESeq2 (Love et al., 2014)) in MCF7 cells in response 
to one-hour treatment with recombinant human IL6 as determined by RNA-seq (n=4). (B) Enrichment 
of shared pSTAT3-ER binding sites (dashed line) and sites only bound by pSTAT3 (solid line) in the 
vicinity of IL6-induced genes (blue) compared to an equal number of constitutively expressed genes 
(grey) in MCF7 cells. Lines illustrate the cumulative percentage of sites within a given distance from 
the TSS. (C) Percentage of breast cancer ATAC-seq peaks occupied by pSTAT3 and ER in patients 
(Figure 3C) that are connected to IL6 target gene promoters from T47D cells through promoter-
enhancer connections (Corces et al., 2018) (Red line). The distribution of connections between 
random ATAC-seq peaks and IL6 target gene promoters is shown for comparison in blue (10,000 
iterations to estimate the distribution of the test statistic under the null hypothesis). *Approximate 
random permutation p value <0.0001. (D) Number of binding sites occupied by pSTAT3 and/or ER 
that contain expression quantitative trait loci (eQTL) linked to expression of IL6 target genes in T47D 
cells (Figure 4A) (blue) or the same number of random expressed genes (grey) were determined using 
eQTL data from the GTEx Portal (GTEx_Analysis_v8_eQTL.tar was downloaded on 11/14/2019). 
Error bars indicate standard deviations from 1,000 random permutations. *p<0.001 (1,000 iterations 
to estimate the distribution of the test statistic under the null hypothesis). 
  
 
Figure S6. Western blot, ATAC-seq and RNA-seq after transcription factor perturbations in 
MCF7 and T47D cells, Related to Figure 5.  
(A) Western blot showing siRNA-mediated knock down of STAT3, ER and FOXA1 in T47D cells 
after 48 h. Representative of two independent biological replicates. (B,C) MA plot showing changes 
in ATAC-seq signal in response to IL6 under siControl (ciCtl) conditions (B) or in response to 
FOXA1 knock down under IL6-stimulated conditions (C) (n=3). Red points indicate significant 
changes (padj<0.05, DiffBind (Stark and Brown, 2011)). (D) UCSC genome browser screen shots 
for representative IL6- and FOXA1-dependent ATAC-seq peaks from Figure 5A,B 
(http://genome.ucsc.edu, Dec. 2013 GRCh38/hg38) (Kent et al., 2002). (E) Analysis of motif 
enrichment in IL6- and FOXA1-dependent ATAC-seq peaks (see Figure 5A,B) was performed using 
ER, FOXA1 and STAT3 motif matrices from the Jaspar database (Mathelier et al., 2016). The 
enrichment was calculated as the number of motif instances in each group of sites relative to the 
number of motif instances in the same number of random T47D ATAC-seq peaks from the IL6 
condition. (F) Genomic distribution of IL6- and FOXA1-dependent ATAC-seq peaks (see Figure 
5A,B). (G) Regulation of the transcriptional response to one hour of IL6 treatment (padj<0.05, 
DESeq2 (Love et al., 2014)) upon depletion of STAT3, ER, or FOXA1 as determined by RNA-seq 
in T47D cells (n=4). (H) Western blot showing knock out of STAT3 and response to fulvestrant in 
MCF7 cells. WT is the parental wild-type MCF7 clone expressing luciferase and mStrawberry used 
to make the two STAT3-/- clones. Representative of two independent biological replicates. (I) Overlap 
between IL6- and FOXA1-dependent genes as determined by RNA-seq in T47D cells (n=4). FOXA1-
dependent genes were defined as those with padj<0.05 and Log2 fold change<-0.5 (DESeq2 (Love 
et al., 2014)) comparing siFOXA1-IL6 to siControl-IL6. IL6-dependent genes were defined as those 
with padj<0.05 and Log2 fold change>0.5 comparing siControl-IL6 to siControl-Veh. (J) Heatmap 
showing a general repression of the Hallmark Estrogen response early gene set (Liberzon et al., 2015) 
in response to four hours of fulvestrant treatment of the MCF7 cells from panel H as determined by 





Figure S7. Univariate and multivariate analyses and response of the IL6 gene program to 
treatment, Related to Figure 6.  
(A,B) Univariate and multivariate analyses of the prognostic significance of well-established breast 
cancer marker proteins (i.e. ER, HER2, PR, Ki67) and pSTAT3Y705 for 10 year BCSS (A) and OS 
(B) in the Nottingham cohort (Ahmad et al., 2018; Aleskandarany et al., 2016). p values were 
determined by Cox regression analyses. (C) Regulation of Hallmark early estrogen responsive genes 
(n=200) (Liberzon et al., 2015) and IL6-induced genes (n=328 for T47D and n=67 for MCF7) in 
matched samples from 81 patients treated with anastrozole for two weeks prior to surgery (Dunbier 
et al., 2013). The mean regulation of 200 random genes is included for comparison with the error bar 
representing the standard deviation of 1,000 iterations. *p=0.00038 and **p=4.0e-13 (Fisher’s exact 
test, two-sided). The schematic illustration was created with BioRender.com. (D) Schematic 
overview of the explant approach used to culture ER+ PDX tumors ex vivo. (E) Representative images 
of H&E and IHC for pSTAT3Y705 in a WT ER+/PR- PDX (STG335) (Bruna et al., 2016) explant 
treated with vehicle (Veh), IL6 (50 ng/ml) or IL6+Ruxolitinib (500 nM) for two days ex vivo. Scale 
bar = 50 µm.  (F) Quantification of pSTAT3Y705 IHC staining in the PDX explant from panel E using 
the Halo TM (Indica labs) Image analysis platform. Error bars represent SEM between different 
tumor pieces (n=3-4) from different parts of the PDX tumor cultured on the same sponge. *p<0.05, 
**p<0.01 (Student’s t-test, two-sided). (G) Quantification of PR expression in the PDX from Figure 
6E as determined by IHC. Error bars represent SEM, n=4-5. **p<0.01, ***p<0.001 (One way 
ANOVA, followed by Tukey’s multiple comparison test). 
